CTOs on the Move

Family Care Network

www.familycarenetwork.com

 
We would love to hear from you! Please private message us with questions or feedback and we will respond as quickly as possible. General guidelines for posting on our page: • Be humane: Behind the computer screen, there are real humans with real fee...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

POZEN

POZEN Inc. is a specialty pharmaceutical company that to date has historically focused on developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage.

Miller Pharmacy

Miller Pharmacy is a Kansas City, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Highfive Vet Wholesale

Automated purchasing for vet clinics | Less mundane tasks. More time for your mission.

Affordable Quality Pharmaceuticals

Affordable Quality Pharmaceuticals is a Garden Grove, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aspyrian Therapeutics

Aspyrian Therapeutics is a new start-up located in San Diego (California, USA) that focuses on developing novel targeted therapies for Oncology, Inflammation, and Pain. Aspyrian Therapeutics and its collaborators are developing novel cancer targeted therapies based on proprietary technologies that achieve highly specific and tumor restricted anticancer activity. Tumor specific action serves to avoid damage to healthy organs for enhanced anticancer activity and increased safety profile. Aspyrian Therapeutics has secured the exclusive license from the National Cancer Institute for a new Antibody Conjugate Technology: Near-infrared Photoimmunotherapy (PIT). PIT permits highly efficient and selective ablation of tumor cells while sparing damage to critical structures adjacent to the tumor.